Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center 'real-life' cohort
| Autor: | Jörn M. Schattenberg, Anita Pathil, Thomas Zimmerer, Christoph Antoni, Tim Zimmermann, Peter R. Galle, Martin F. Sprinzl, Wolfgang Stremmel, Kerstin Stein, N Steinebrunner, Marcus A. Wörns, Christoph Eisenbach |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Liver Cirrhosis Male medicine.medical_specialty Time Factors Combination therapy Sofosbuvir Alpha interferon Hepacivirus Antiviral Agents Gastroenterology Polyethylene Glycols Young Adult chemistry.chemical_compound 610 Medical sciences Medicine Internal medicine Ribavirin medicine Humans Longitudinal Studies Aged Retrospective Studies business.industry Interferon-alpha virus diseases Retrospective cohort study General Medicine Hepatitis C Chronic Middle Aged Viral Load Hepatology Recombinant Proteins digestive system diseases Treatment Outcome chemistry Retreatment Cohort Immunology RNA Viral Drug Therapy Combination Female business Viral load Research Article medicine.drug |
| Zdroj: | BMC Gastroenterology |
| ISSN: | 1471-230X |
| DOI: | 10.1186/s12876-015-0328-9 |
| Popis: | Background: The combination of sofosbuvir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the combination of SOF and RBV for the treatment of patients infected with hepatitis c virus (HCV) has improved rates of sustained virological response (SVR) considerably in recent trials. However, there is only limited data concerning the efficacy and safety in a “real-life” cohort. Methods: We analyzed a cohort of 119 patients with chronic HCV infection treated at four investigational sites in Germany. All patients received either a combination treatment of SOF, RBV and peg-IFN-alfa-2a or SOF and RBV. Results: The rates of SVR at 12 weeks after end of treatment (SVR 12) were as follows: Among 76 patients with genotype 1 infection the SVR 12 rate was 74 % (n = 56), among 14 patients with genotype 2 infection the SVR 12 rate was 79 % (n = 11), among 24 patients with genotype 3 infection the SVR 12 rate was 92 % (n = 22) and among 5 patients with genotype 4 infection the SVR 12 rate was 80 % (n = 4). Of all 26 patients with a relapse in our cohort, 69 % (n = 18) of these patients presented with liver cirrhosis and 58 % (n = 15) were treatment experienced. Notably, the level of HCV-RNA after 4 weeks of treatment was a significant predictor of treatment response in genotype 1 patients. Patients with HCV-RNA levels ≥ 12 IU ml-1 after 4 weeks of treatment achieved SVR 12 only in 30 % (n = 17/56, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink